Navigation Links
United Therapeutics Subsidiary Enters Into Contract With National Institutes of Health for Award of up to $45 Million to Support Glycobiology Antiviral Program
Date:10/10/2011

SILVER SPRING, Md., Oct. 10, 2011 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) announced that its subsidiary, Unither Virology, LLC, has been awarded a contract for up to approximately $45 million under a Broad Agency Announcement from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), for studies directed at the development of a broad-spectrum antiviral drug based on its glycobiology antiviral platform.  Based on the support from this contract, approximately 20 jobs will be created at Unither Virology's headquarters in Silver Spring, Maryland, with additional jobs created at subcontractor organizations.

"I'm pleased with the development of our broad-spectrum antiviral program, which is in the preclinical stage," remarked Martine Rothblatt, Ph.D., United Therapeutics' Chairman and Chief Executive Officer. "The overall objective for this partnership with NIH is to develop a safe and orally available broad-spectrum antiviral drug to treat viruses such as dengue and influenza.  Dengue is a painful mosquito-borne tropical fever suffered by millions of patients worldwide each year, and this program may help provide a path to treatment.  It is also rewarding to see how our industry generates dozens of jobs when the science data justify expanding a program to its next stage of growth."

The contract provides for up to approximately $45 million in total funding over five years.  The base period of 42 months includes approximately $10.6 million in funding.  The remaining funds are allocated to eight milestone-based options.  Funding will support the development of a candidate compound through preclinical safety and efficacy studies toward potential clinical trials against dengue, as well as preclinical studies to develop additional data against influenza.

'/>"/>

SOURCE United Therapeutics Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Full-day "United Nations" Online Investor Conference: October 6th at RetailInvestorConferences.com
2. United Therapeutics Corporation Reports Second Quarter 2011 Financial Results
3. FDA Advisory Panel Unanimously Recommends Approval of EXCOR(R) Pediatric Ventricular Assist Device for Use in the United States
4. Daiichi Sankyo Selects Veeva CRM to Support Customer Engagement Initiatives in the United Kingdom
5. United Therapeutics Corporation To Announce Second Quarter 2011 Financial Results Before Market Open on Thursday, July 28, 2011
6. United Therapeutics Corporation Completes Enrollment of FREEDOM-C(2) Trial
7. United Therapeutics Corporation Reports 2010 Fourth Quarter and Annual Financial Results
8. United Therapeutics Corporation to Announce Fourth Quarter and Annual 2010 Financial Results Before Market Open on Tuesday, February 15, 2011
9. United Therapeutics Corporation Reports Third Quarter 2010 Financial Results
10. United Therapeutics Corporation to Announce Third Quarter 2010 Financial Results Before Market Open on Thursday, October 28, 2010
11. Sangart, Inc. Receives $1.1 Million Grant Award from the United States Department of Defense for Further Development of MP4 Molecule in Trauma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... , July 30, 2015 AACC ... to the 2015 AACC Annual Meeting & Clinical ... from July 26–30. The meeting showcased revolutionary advancements ... the ability of healthcare providers to diagnose patients ... effective medical treatment. As of ...
(Date:7/30/2015)... VANCOUVER, Washington , July 30, 2015 ... "Biosimulation Market, by Product (Software, Molecular Modeling, PB/PK, PKPD, ... (Drug Discovery & Development, Preclinical, Clinical Trial), by End ... the Biosimulation Market is expected to reach USD 2,107.99 ... at a CAGR of 15.29%. Browse ...
(Date:7/30/2015)... globe, ISN improves the efficiency and effectiveness of contractor management systems. ISN,s online contractor ... in over 80 countries. ... ... Over 60,000 Worldwide Customers In More Than 80 Countries ... Dallas, TX , ISN has additional offices in Calgary , ...
(Date:7/30/2015)... ... 30, 2015 , ... As part of its 2015 growth plan and as a follow up ... business units, Whitehouse Laboratories is pleased to announce that it has begun construction on ... of Excellence and will be strictly dedicated to basic USP 51, USP 61, and USP ...
Breaking Biology Technology:Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 2Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 3Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 4Biosimulation Market Worth 2,107.99 Million USD by 2020 2Biosimulation Market Worth 2,107.99 Million USD by 2020 3Biosimulation Market Worth 2,107.99 Million USD by 2020 4ISN Reaches Over 60,000 Worldwide Customers 2ISN Reaches Over 60,000 Worldwide Customers 3Whitehouse Labs Formally Announces Plans to Open a Microbiological Laboratory 2
... VIENNA, Va., June 4 In response to ... is providing an,update on the construction of its ... built out, will comprise 73,000 square,feet and will ... product. This dedicated facility will produce the Multikine ...
... Research, MELVILLE, N.Y., June 4 ... University,s Feinberg School of,Medicine announced the opening ... a partnership that brings improved research,capabilities to ... development. One of only three such centers ...
... (OTC Bulletin Board: BSTC.OB) today announced that it,sold ... at $13 per,share with aggregate proceeds to BioSpecifics ... group on May 30, 2008. The shares were ... premium over the market price., BioSpecifics Technologies ...
Cached Biology Technology:CEL-SCI CORPORATION Manufacturing Facility for Pivotal Phase III Cancer Trial Scheduled to Be Completed During 2008 Third Quarter 2CEL-SCI CORPORATION Manufacturing Facility for Pivotal Phase III Cancer Trial Scheduled to Be Completed During 2008 Third Quarter 3Nikon Instruments Opens New Imaging Center at Northwestern University 2Nikon Instruments Opens New Imaging Center at Northwestern University 3
(Date:7/30/2015)... MOUNTAIN VIEW, Calif. , July 30, 2015 ... products and services for gene function analysis and ... CRISPR Guide RNA (sgRNA) Knockout Library targeting all ... to specifically and permanently "knock out" a gene,s ... library provides a high throughput screening tool so ...
(Date:7/23/2015)... July 23, 2015 Aware, Inc. (NASDAQ: AWRE ... reported financial results for its second quarter ended June 30, ... 2015 was $4.5 million, a decrease of 33% compared to ... in the second quarter of 2015 was $0.3 million, or ... $0.04 per diluted share, in the same period a year ...
(Date:7/21/2015)... Connecticut , July 21, 2015  NXT-ID, ... "Company"), a biometric authentication company focused on the ... Wocket® smart wallet, announces that it has filed ... System and Method. This invention ... not only authorizes an account, but also the ...
Breaking Biology News(10 mins):CELLECTA, INC. Announces Launch of Human Whole Genome CRISPR Knockout Library 2Aware, Inc. Reports Second Quarter 2015 Financial Results 2Aware, Inc. Reports Second Quarter 2015 Financial Results 3Aware, Inc. Reports Second Quarter 2015 Financial Results 4Aware, Inc. Reports Second Quarter 2015 Financial Results 5Aware, Inc. Reports Second Quarter 2015 Financial Results 6NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 2NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 4
... pair of proteins that work in concert to restart the ... The Hawley Lab has described the dual actions ... awakens the long-dormant egg, allowing for production of a mature ... 4, 2007 issue of PLoS Biology. The long ...
... from the John Innes Centre have proven that by ... and delivering it with an existing antibiotic they can ... transfer company PBL, the scientists have launched a spin-out ... The DNA sequence acts as a decoy, disrupting gene ...
... severe weather and climate change joined forces to study ... severe storms in the future and discovered a dramatic ... the United States. The Purdue University-led team used ... formation of severe thunderstorms - those that produce flooding, ...
Cached Biology News:Stowers Institute's Hawley Lab identifies factors responsible for restart of meiotic cycle 2Decoy makes sitting duck of superbugs 2Research forecasts increased chances for stormy weather 2Research forecasts increased chances for stormy weather 3Research forecasts increased chances for stormy weather 4Research forecasts increased chances for stormy weather 5
Monoclonal mouse antibody for immunihistology, clone AD12, Isotype IgG 1, purified, specific for rat pyruvatekinase type L, no cross-reactivities with other pyruvate kinase isoenzymes have been obser...
For testing the AQUA technique on your MS instruments....
A robust formulation of Taq Polymerase supplied with a 10X colored reaction buffer which allows Direct Gel-Loading...
... Dinitro-5,5'-dithiodibenzoic acid , DTNB , Ellman's reagent ... , *CAS-No.: 69-78-3 *Storage: RT, ... a reactive grouping not present in the substrate, ... which will react directly with the product to ...
Biology Products: